NCT03850626 is a clinical trial of Immunotherapy in Allergic Rhinoconjunctivitis, sponsored by Leti Pharma GmbH.

Who is sponsoring NCT03850626?

NCT03850626 is sponsored by Leti Pharma GmbH.

What drugs are being tested in NCT03850626?

Interventions in NCT03850626: Immunotherapy.

What condition does NCT03850626 study?

NCT03850626 studies Allergic Rhinoconjunctivitis, Allergic Asthma.

Is NCT03850626 still recruiting?

NCT03850626 is currently completed. Last updated 26 March 2021.

Last reviewed 2021-03-26 · How we verify

NCT03850626

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients

Completed Last updated 26 March 2021

What this trial tests

trial testing Immunotherapy in Allergic Rhinoconjunctivitis in 168 participants. Completed in 3 September 2020.

Timeline

9 September 2018

Primary endpoint
3 September 2020

3 September 2020

Quick facts

Lead sponsor	Leti Pharma GmbH
Status	Completed
Study type	OBSERVATIONAL
Enrollment	168
Start date	9 September 2018
Primary completion	3 September 2020
Estimated completion	3 September 2020
Sites	1 location across Germany

Drugs / interventions tested

Immunotherapy — full drug profile →

Conditions studied

Allergic Rhinoconjunctivitis — all drugs for Allergic Rhinoconjunctivitis →
Allergic Asthma — all drugs for Allergic Asthma →

Sponsor

Leti Pharma GmbH — full company profile →

Who can join

12 and older, any sex, with Allergic Rhinoconjunctivitis or Allergic Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CSMS was defined by the European Academy of Allergy and Immunology Taskforce as a standardised tool to assess clinical effects of allergen-specific immunotherapy (AIT). The aim of this study is to validate the CSMS as a tool to assess the clinical effects of Depigoid AIT, so that the CSMS can be used in future studies as a primary endpoint as well as a comparative parameter.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Correlation of the combined symptom and medication score with quality of life, symptom severity and symptom control in allergic rhinoconjunctivitis.
Palathumpattu B, Pieper-Fürst U, Acikel C, Sahin H, et al · · 2022 · cited 8× · PMID 36225263 · DOI 10.1002/clt2.12191
Dogmas, challenges, and promises in phase III allergen immunotherapy studies.
De Kam PJ, Kramer MF, Shamji MH, Oluwayi K, et al · · 2021 · cited 6× · PMID 34659627 · DOI 10.1016/j.waojou.2021.100578

Verify or expand the search:

Other trials of Immunotherapy

Trials testing the same drug.

NCT07293247 — A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After · Phase 2 · not yet recruiting
NCT07259473 — Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma · Phase 2 · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
NCT07297030 — SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer · Phase 2 · not yet recruiting
NCT07231575 — Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC · Phase 2 · not yet recruiting

Other recruiting trials for Allergic Rhinoconjunctivitis

Currently open trials in the same condition.

NCT06778213 — Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomi · Phase 4 · recruiting

Other Leti Pharma GmbH trials

Trials by the same sponsor.

NCT01694836 — Depigoid Birch 5000 Longterm Study in Adults and Adolescents · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03850626 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Leti Pharma GmbH
Last refreshed: 26 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03850626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing